SM
CLDI icon

Sabby Management’s Calidi Biotherapeutics CLDI Stock Holding History

Sabby Management’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-27,181
Closed -$104K – 28
2026
Q1 		$104K Buy
+27,181
New +$327K 0.23% 23

Other funds holding CLDI

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $533M AUM 20.75% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Sabby Management's CLDI Position: Q2 2026 in Review

Sabby Management sold out of Calidi Biotherapeutics (CLDI) in Q2 2026, closing a stake of 27,181 shares — an estimated $104K sold.

Sabby Management first reported a position in CLDI in Q1 2026 and held it in 1 quarter. The position peaked at $104K in Q1 2026. 22 funds tracked by Wall St. Rank hold CLDI as of Q2 2026.

  • Sabby Management reported no remaining Calidi Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Sabby Management sold 27,181 Calidi Biotherapeutics shares in Q2 2026, an estimated $104K.
  • Sabby Management first reported a position in Calidi Biotherapeutics in Q1 2026 and held it in 1 quarter.
  • Sabby Management's Calidi Biotherapeutics position peaked at $104K in Q1 2026.
  • 22 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q2 2026.

Based on Sabby Management's 13F filing for Q2 2026, filed 14 Aug 2026.